Seastar Medical Holding CORP 8-K filings

SeaStar Medical announced Q2 2026 financial results, showcasing an 82% increase in QUELIMMUNE net revenue and advancements in its NEUTRALIZE-AKI trial, alongside obtaining crucial billing codes.

SeaStar Medical Holding Corporation has entered into retention bonus agreements with executives Eric Schlorff and Kevin Chung, including cash payments and potential restricted stock units, to incentivize continued employment.

SeaStar Medical Holding Corporation held its annual stockholder meeting, approving an amendment to increase shares available under its 2022 Omnibus Incentive Plan.

SeaStar Medical announced a 69% year-over-year increase in first-quarter revenue driven by QUELIMMUNE sales and provided updates on its pivotal trials for adult AKI treatment.

SeaStar Medical Holding Corporation announced the dismissal with prejudice of a putative class action lawsuit alleging material misstatements and omissions.

SeaStar Medical announced significant revenue growth and clinical trial advancements for its life-saving therapies in its Q4 and full-year 2025 financial results.

SeaStar Medical Holding Corporation announced it has regained compliance with Nasdaq's minimum bid price requirement, effective January 20, 2026.

SeaStar Medical Holding Corporation announced a revised effective date for its 1-for-10 reverse stock split, now set for January 5, 2026, to meet Nasdaq listing requirements.

SeaStar Medical Holding Corporation's shareholders approved a 1-for-10 reverse stock split and a reduction in authorized shares at a special meeting on December 18, 2025.

SeaStar Medical Holding Corporation has appointed Michael Messinger, a seasoned healthcare executive, as its new Chief Financial Officer, effective November 14, 2025.

SeaStar Medical announced strong third-quarter 2025 financial results and significant progress in its clinical trials and commercial product adoption, including a $12.4 million capital raise.

SeaStar Medical Holding Corporation announced increases in executive salaries and restored director cash retainers, effective October 1, 2025, reversing prior cost-cutting measures.

SeaStar Medical's pivotal NEUTRALIZE-AKI trial for its Selective Cytopheretic Device (SCD) therapy will continue, with an increased patient enrollment target to strengthen statistical power.

SeaStar Medical Holding Corporation announced the termination of its Chief Financial Officer, David Green, and the appointment of CEO Eric Schlorff as interim CFO.

SeaStar Medical reports progress in its NEUTRALIZE-AKI trial, positive QUELIMMUNE survival data, and a significant capital raise, extending its financial runway into 2026.

SeaStar Medical announced improved Q2 2025 financial results, significant progress in its NEUTRALIZE-AKI trial, and expanded adoption of its QUELIMMUNE therapy.

SeaStar Medical Holding Corporation has resumed its At-the-Market offering, aiming to raise up to an additional $2.17 million for general corporate purposes.

SeaStar Medical Holding Corporation received a Nasdaq deficiency letter for failing to meet the minimum $1.00 bid price requirement, with 180 days to regain compliance.

SeaStar Medical Holding Corporation received a deficiency letter from Nasdaq for failing to meet the minimum $1.00 bid price requirement, initiating a 180-day compliance period.

SeaStar Medical Holding Corporation announced a definitive agreement to issue 4,960,544 shares and warrants in a registered direct offering and concurrent private placement, raising approximately $4.4 million in gross proceeds.

SeaStar Medical Holding Corporation announced the appointment of seasoned healthcare executive Jennifer A. Baird as the new Chair of its Board of Directors, succeeding Rick J. Barnett who resigned for personal reasons.

SeaStar Medical Holding Corporation announced a $4 million registered direct offering and concurrent private placement of common stock and warrants to fund general corporate purposes, including ongoing clinical trials and commercialization efforts.

SeaStar Medical Holding Corporation announced that its stockholders approved the election of two Class III Directors, an amendment to its equity incentive plan, and a potential future stock issuance to Lincoln Park at its annual meeting on July 3, 2025.

SeaStar Medical Holding Corporation has confirmed regaining compliance with Nasdaq's minimum stockholders' equity requirement, though Nasdaq has mandated the company raise additional funds by the end of July to maintain its listing.

SeaStar Medical announced the pricing of a public offering to raise up to $8 million, alongside significant cost-cutting measures and liability restructuring, to regain and maintain Nasdaq listing compliance.

SeaStar Medical Holding Corporation's CEO and CMO have waived their earned bonuses for 2023 and 2024 to support the company's efforts in reducing liabilities.

SeaStar Medical announced a four-fold increase in sequential quarter net revenue driven by QUELIMMUNE adoption, along with progress in the NEUTRALIZE-AKI trial.

SeaStar Medical Holding Corporation has entered into a purchase agreement with Lincoln Park Capital for up to $15 million in shares of common stock to bolster working capital and general corporate purposes.

SeaStar Medical Holding Corporation announces stockholder approval of key proposals related to warrant issuance and extension at a special meeting held on March 28, 2025.

SeaStar Medical announced its financial results for the three months and year ended December 31, 2024, along with business updates, highlighting FDA approval for QUELIMMUNE and progress in the NEUTRALIZE AKI trial.